Vir Biotechnology Stock Forecast, Price & News

-0.53 (-1.43 %)
(As of 07/27/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume692,509 shs
Average Volume1.25 million shs
Market Capitalization$4.74 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive VIR News and Ratings via Email

Sign-up to receive the latest news and ratings for Vir Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Vir Biotechnology logo

About Vir Biotechnology

Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.01 out of 5 stars

Medical Sector

569th out of 2,218 stocks

Biological Products, Except Diagnostic Industry

82nd out of 213 stocks

Analyst Opinion: 3.2Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Vir Biotechnology (NASDAQ:VIR) Frequently Asked Questions

Is Vir Biotechnology a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vir Biotechnology in the last twelve months. There are currently 2 sell ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Vir Biotechnology stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VIR, but not buy additional shares or sell existing shares.
View analyst ratings for Vir Biotechnology
or view top-rated stocks.

What stocks does MarketBeat like better than Vir Biotechnology?

Wall Street analysts have given Vir Biotechnology a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Vir Biotechnology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Vir Biotechnology's next earnings date?

Vir Biotechnology is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Vir Biotechnology

How can I listen to Vir Biotechnology's earnings call?

Vir Biotechnology will be holding an earnings conference call on Thursday, August 5th at 4:00 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Vir Biotechnology's earnings last quarter?

Vir Biotechnology, Inc. (NASDAQ:VIR) posted its earnings results on Thursday, May, 6th. The company reported ($1.32) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $1.09. The business had revenue of $1.98 million for the quarter, compared to analysts' expectations of $170.53 million. Vir Biotechnology had a negative trailing twelve-month return on equity of 56.90% and a negative net margin of 537.47%.
View Vir Biotechnology's earnings history

How has Vir Biotechnology's stock price been impacted by COVID-19?

Vir Biotechnology's stock was trading at $33.77 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, VIR shares have increased by 7.9% and is now trading at $36.44.
View which stocks have been most impacted by COVID-19

What price target have analysts set for VIR?

7 Wall Street analysts have issued 12-month price objectives for Vir Biotechnology's shares. Their forecasts range from $24.00 to $135.00. On average, they anticipate Vir Biotechnology's share price to reach $66.00 in the next year. This suggests a possible upside of 81.1% from the stock's current price.
View analysts' price targets for Vir Biotechnology
or view top-rated stocks among Wall Street analysts.

Who are Vir Biotechnology's key executives?

Vir Biotechnology's management team includes the following people:
  • Dr. George A. Scangos, Pres, CEO & Director (Age 73, Pay $994.88k)
  • Mr. Howard Horn, CFO & Sec. (Age 43, Pay $681.83k)
  • Dr. Herbert W. Virgin IV, Exec. VP of Research & Chief Scientific Officer (Age 65, Pay $1.11M)
  • Mr. Steven J. Rice, Chief Admin. Officer (Age 61, Pay $698.62k)
  • Dr. Klaus Frueh, Co-Founder & Scientific Advisor (Age 61)
  • Dr. Lawrence Corey, Co-Founder & Scientific Advisor
  • Dr. Louis J. Picker, Co-Founder & Scientific Advisor
  • Dr. Aine M. Hanly Ph.D., Chief Technology Officer (Age 51)
  • Dr. Neera Dahiya Ravindran M.D., MBA, VP and Head of Investor Relations & Strategic Communications
  • Ms. Irene Pleasure J.D., Ph.D., Sr. VP & Gen. Counsel

What is George Scangos' approval rating as Vir Biotechnology's CEO?

7 employees have rated Vir Biotechnology CEO George Scangos on George Scangos has an approval rating of 85% among Vir Biotechnology's employees.

Who are some of Vir Biotechnology's key competitors?

When did Vir Biotechnology IPO?

(VIR) raised $149 million in an IPO on Friday, October 11th 2019. The company issued 7,100,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays acted as the underwriters for the IPO.

What is Vir Biotechnology's stock symbol?

Vir Biotechnology trades on the NASDAQ under the ticker symbol "VIR."

How do I buy shares of Vir Biotechnology?

Shares of VIR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vir Biotechnology's stock price today?

One share of VIR stock can currently be purchased for approximately $36.44.

How much money does Vir Biotechnology make?

Vir Biotechnology has a market capitalization of $4.74 billion and generates $76.37 million in revenue each year. The company earns $-298,670,000.00 in net income (profit) each year or ($2.51) on an earnings per share basis.

How many employees does Vir Biotechnology have?

Vir Biotechnology employs 340 workers across the globe.

What is Vir Biotechnology's official website?

The official website for Vir Biotechnology is

Where are Vir Biotechnology's headquarters?

Vir Biotechnology is headquartered at 499 ILLINOIS STREET SUITE 500, SAN FRANCISCO CA, 94158.

How can I contact Vir Biotechnology?

Vir Biotechnology's mailing address is 499 ILLINOIS STREET SUITE 500, SAN FRANCISCO CA, 94158. The company can be reached via phone at 415-906-4324 or via email at [email protected]

This page was last updated on 7/28/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.